228 related articles for article (PubMed ID: 29171774)
1. Advances in treating psoriasis in the elderly with small molecule inhibitors.
Cline A; Cardwell LA; Feldman SR
Expert Opin Pharmacother; 2017 Dec; 18(18):1965-1973. PubMed ID: 29171774
[TBL] [Abstract][Full Text] [Related]
2. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Yiu ZZ; Warren RB
Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibitors in chronic plaque psoriasis: What is known so far.
Plachouri KM; Georgiou S
Drugs Today (Barc); 2020 Feb; 56(2):151-163. PubMed ID: 32163530
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
5. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
McAndrew R; Levin E; Koo J
J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
[TBL] [Abstract][Full Text] [Related]
6. Small molecule therapy for managing moderate to severe psoriatic arthritis.
Costa L; Del Puente A; Peluso R; Tasso M; Caso P; Chimenti MS; Sabbatino V; Girolimetto N; Benigno C; Bertolini N; Del Puente A; Perricone R; Scarpa R; Caso F
Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
[TBL] [Abstract][Full Text] [Related]
7. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Caso F; Navarini L; Ruscitti P; Chimenti MS; Girolimetto N; Del Puente A; Giacomelli R; Scarpa R; Costa L
Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Zhang L; Guo L; Wang L; Jiang X
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
10. Oral small molecules for psoriasis.
Singh S; Armstrong AW
Semin Cutan Med Surg; 2018 Sep; 37(3):163-166. PubMed ID: 30215633
[TBL] [Abstract][Full Text] [Related]
11. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Artamonova OG; Karamova AE; Nikonorov AA; Verbenko DA; Vasileva EL; Kubanov AA
Bull Exp Biol Med; 2021 May; 171(2):208-211. PubMed ID: 34173094
[TBL] [Abstract][Full Text] [Related]
13. Apremilast for the treatment of psoriasis.
Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
[TBL] [Abstract][Full Text] [Related]
14. Oral small molecules for the treatment of atopic dermatitis: a systematic review.
Mobasher P; Heydari Seradj M; Raffi J; Juhasz M; Atanaskova Mesinkovska N
J Dermatolog Treat; 2019 Sep; 30(6):550-557. PubMed ID: 30501539
[No Abstract] [Full Text] [Related]
15. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
16. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
17. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Palfreeman AC; McNamee KE; McCann FE
Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Westhovens R
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i27-i33. PubMed ID: 30806706
[TBL] [Abstract][Full Text] [Related]
19. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
Torres T; Puig L
Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
[TBL] [Abstract][Full Text] [Related]
20. Apremilast as a treatment for psoriasis.
Shutty B; West C; Pellerin M; Feldman S
Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
